B7-H3/CD276:新型免疫检查站和万事达人
Brigid Larkin1, Daisuke Nishizaki1, Hirotaka Miyashita2
1Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
ImmunoTargets and therapy
|September 12, 2025
概括
B7-H3/CD276是一种复杂的免疫调节蛋白. 向B7-H3/CD276在癌症治疗中具有前景,特别是在表达高的患者中,尽管其免疫功能不完全定义.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫疗法已经彻底改变了癌症治疗,但抗药性仍然是一个重大挑战.
- B7-H3 / CD276,B7家族成员,是一种免疫调节分子,在免疫激活和抑制中具有复杂的,取决于环境的作用.
- 它的表达在各种癌症和炎症状况中被注意到,在恶性瘤类型中观察到异质的模式.
研究的目的:
- 阐明B7-H3/CD276在癌症发病和进展中的免疫和代谢作用.
- 分析B7-H3 / CD276在泛癌队列中的异质RNA表达模式.
- 总结B7-H3/CD276向疗法的早期临床试验结果.
主要方法:
- 在泛癌数据集中对B7-H3/CD276RNA表达的生物信息分析.
- 对B7-H3/CD276.6的免疫和代谢功能的现有文献的审查.
- 从涉及B7-H3/CD276向剂的早期临床试验中收集和总结数据.
主要成果:
- B7-H3/CD276在不同癌症类型中甚至在同一癌症中表现出不同的表达水平.
- 初步的临床数据表明B7-H3/CD276向剂的治疗活性,特别是在B7-H3/CD276.6瘤表达高的患者中.
- 该研究详细介绍了B7-H3 / CD276在癌症免疫和新陈代谢中的作用.
结论:
- B7-H3/CD276代表了新型癌症免疫疗法的一个有希望的目标.
- 了解B7-H3/CD276的异质表达和复杂功能对于优化其治疗应用至关重要.
- 需要进一步的研究和临床试验,以充分利用B7-H3 / CD276作为抗癌标.
相关概念视频
B Cell Activation and Differentiation
16.1K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
16.1K
T Cell Activation and Clonal Selection
14.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K


